A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

529

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: MenACWY-CRM
BIOLOGICAL: DTaP-IPV/Hib
BIOLOGICAL: HBV
BIOLOGICAL: PCV
BIOLOGICAL: MMR

Sponsor

Novartis Vaccines